These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 12117418)

  • 1. Structural and functional characterization of tissue factor pathway inhibitor following degradation by matrix metalloproteinase-8.
    Cunningham AC; Hasty KA; Enghild JJ; Mast AE
    Biochem J; 2002 Oct; 367(Pt 2):451-8. PubMed ID: 12117418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The second Kunitz domain of human tissue factor pathway inhibitor: cloning, structure determination and interaction with factor Xa.
    Burgering MJ; Orbons LP; van der Doelen A; Mulders J; Theunissen HJ; Grootenhuis PD; Bode W; Huber R; Stubbs MT
    J Mol Biol; 1997 Jun; 269(3):395-407. PubMed ID: 9199408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure and biology of tissue factor pathway inhibitor.
    Bajaj MS; Birktoft JJ; Steer SA; Bajaj SP
    Thromb Haemost; 2001 Oct; 86(4):959-72. PubMed ID: 11686353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of secreted Kunitz domain 1 variants of tissue factor pathway inhibitor.
    Johnson K; Zaror I; Bauer D; Choi Y; Creasey A; Innis M
    Thromb Haemost; 1998 Oct; 80(4):585-7. PubMed ID: 9798974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factor Xa cleavage of tissue factor pathway inhibitor is associated with loss of anticoagulant activity.
    Salemink I; Franssen J; Willems GM; Hemker HC; Li A; Wun TC; Lindhout T
    Thromb Haemost; 1998 Aug; 80(2):273-80. PubMed ID: 9716152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin.
    Wesselschmidt R; Likert K; Huang Z; MacPhail L; Broze GJ
    Blood Coagul Fibrinolysis; 1993 Oct; 4(5):661-9. PubMed ID: 8292716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role for the Kunitz-3 domain of tissue factor pathway inhibitor-alpha in cell surface binding.
    Piro O; Broze GJ
    Circulation; 2004 Dec; 110(23):3567-72. PubMed ID: 15557366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue factor pathway inhibitor; its structure, function and clinical significance.
    Kato H
    Pol J Pharmacol; 1996; 48(1):67-72. PubMed ID: 9112630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contribution of regions distal to glycine-160 to the anticoagulant activity of tissue factor pathway inhibitor.
    Lockett JM; Mast AE
    Biochemistry; 2002 Apr; 41(15):4989-97. PubMed ID: 11939795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibody specific for tissue factor pathway inhibitor-factor Xa complex: its characterization and application to plasmas from patients with disseminated intravascular coagulation and pre-disseminated intravascular coagulation.
    Ohkura N; Soe G; Kohno I; Kumeda K; Wada H; Kamikubo Y; Shiku H; Kato H
    Blood Coagul Fibrinolysis; 1999 Sep; 10(6):309-19. PubMed ID: 10493212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of leukocyte proteinases on tissue factor pathway inhibitor.
    Petersen LC; Bjørn SE; Nordfang O
    Thromb Haemost; 1992 May; 67(5):537-41. PubMed ID: 1519213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of catalytic cleft and exosite residues of factor VIIa for complex formation with tissue factor pathway inhibitor.
    Iakhiaev A; Ruf W; Rao LV
    Thromb Haemost; 2001 Mar; 85(3):458-63. PubMed ID: 11307815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant tissue factor pathway inhibitor enhances the binding of factor Xa to human monocytes.
    Li A; Chang AC; Peer GT; Wun TC; Taylor FB
    Thromb Haemost; 2001 May; 85(5):830-6. PubMed ID: 11372676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transient high affinity binding of tissue factor pathway inhibitor-factor Xa complexes to negatively charged phospholipid membranes.
    Willems GM; Janssen MP; Salemink I; Wun TC; Lindhout T
    Biochemistry; 1998 Mar; 37(10):3321-8. PubMed ID: 9521652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor.
    Petersen LC; Sprecher CA; Foster DC; Blumberg H; Hamamoto T; Kisiel W
    Biochemistry; 1996 Jan; 35(1):266-72. PubMed ID: 8555184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TFPIbeta, a second product from the mouse tissue factor pathway inhibitor (TFPI) gene.
    Chang JY; Monroe DM; Oliver JA; Roberts HR
    Thromb Haemost; 1999 Jan; 81(1):45-9. PubMed ID: 9974373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of factor X activation at extracellular matrix of fibroblasts during flow conditions: a comparison between tissue factor pathway inhibitor and inactive factor VIIa.
    Valentin S; Reutlingsperger CP; Nordfang O; Lindhout T
    Thromb Haemost; 1995 Dec; 74(6):1478-85. PubMed ID: 8772224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Kunitz 1 and Kunitz 3 domains of tissue factor pathway inhibitor are required for efficient inhibition of factor Xa.
    Peraramelli S; Suylen DP; Rosing J; Hackeng TM
    Thromb Haemost; 2012 Aug; 108(2):266-76. PubMed ID: 22627666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteolysis of tissue factor pathway inhibitor (TFPI) by plasmin: effect on TFPI activity.
    Li A; Wun TC
    Thromb Haemost; 1998 Sep; 80(3):423-7. PubMed ID: 9759622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of leukocyte elastase on tissue factor pathway inhibitor.
    Higuchi DA; Wun TC; Likert KM; Broze GJ
    Blood; 1992 Apr; 79(7):1712-9. PubMed ID: 1558967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.